MD Gastro-intestinal oncology @uzleuven
Joined February 2021
- Tweets126
- Following152
- Followers150
- Likes628
Such exciting PII data 📊 at ESMO2025 and Such a quick press release.
Which checkpoints do make a difference?
-TIM3/VISTA?
-CTLA-4 in specific population?
Are most IO checkpoints already exploited? (Upper GI negative LAG3/TIGIT)
P3 STAR221 was negative. Fc silencing did not change the TIGIT story despite promising P2 EDGE Gastric data. We need to improve go or no go decision and learn from negative trials.
bit.ly/44LsGUT
126
Filip Van Herpe retweeted
📽️At #ASCO25 we spoke to @FilipHerpe
(@UZLeuven) who discussed findings of a retrospective single-center analysis assessing claudin-18.2 expression in #GastroesophagealAdenocarcinoma
Watch now 📷 tinyurl.com/mf7hdn2s
@ASCO #GCsm #GastrointestinalCancer #GIsm
This video is available on the GI Cancer Channel on VJOncology, which is supported by Takeda. Supporters have no influence over the production of content.
New out @myESMO
Breath- and blood-based molecular assessment for gastroesophageal canc... sciencedirect.com/science/ar…
A good overview how screening could be evolving in upper GI cancer
@UZLeuven @KU_Leuven @philippenafteux @svanstraelen1 @JDekervel
Me = renovating oncologist
Out with the old: Getting rid of these taxanes! 🏡
In with the new: maybe we’ll get Some IO’s or ADC’s… so many decisions ;-)
#Oncology
1
5
312
Filip Van Herpe retweeted
🔪Salvage surgery for unifocal progressive metastatic dMMR GI cancer responding to #ICI
ascopubs.org/doi/10.1200/PO.…
Interesting new article in @JCOPO_ASCO from our @UZLeuven / @KU_Leuven team. 💪
@JDekervel, @FilipHerpe, @iBakiTopal, @deroose_c, @decaesteckerj, @WolthuisA et al.
Beautiful review of IO in dMMR and PMMR CRC in collaboration with Tejparlab
@GJRas @uzleuven @kuleuven
#weneedbiomarkerdataonpMMRCRC
📘🧬Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers
@NatRevClinOncol
➡️dMMR, metastatic ✅
➡️dMMR, neadjuvant, rectal ✅
➡️dMMR, neadjuvant, colon ✅
⚡️pMMR, biomarkers to select patients who repond well ❓
👉doi.org/10.1038/s41571-024-0…
@OncoAlert @NatureRevCancer @MyriamChalabi #cancer #oncology #MedX
Filip Van Herpe retweeted
Baanbrekende studie TRANSMET toont het aan: patiënten met uitgezaaide dikkedarmkanker naar de lever kunnen geholpen worden met een #levertransplantatie. "Voor jongere kankerpatiënten met een levertumor uit de darm betekent dit de kans op een nieuw leven."
bit.ly/3XdKNzF
Speaking in the “Lions Denn” amongst surgeons about treating gastric cancer
#RBSS #thermaepalace #DIOLeuven #uzleuven
2
7
409
Filip Van Herpe retweeted
Great @EORTC spring meeting on #gicancers in Brussels today. Lots of interesting sessions and expert discussion on (future) trial design. Connecting 🇪🇺 GI cancer research. 🤝
@myESMO @ASCO @FilipHerpe @UZLeuven @Stkstichting @komop_tgkanker #bethere #crc
Again a great randomized study in supportive care for patients treated with 5FU. – at Louvain, Belgium
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology
Simple solutions to seemingly complex problems👇
@JCO_ASCO #ASCO23 ascopubs.org/doi/10.1200/JCO…
2
214
Impressive results for MSS Neoadjuvant CRC. @pashtoonkasi @ASCO #GI24
Remaining questions:
Severity of toxicity? Delay in surgery?
cTNM staging of all patients?
Correlation cTNM VS pTNM difficult
Any ctDNA data?
How did you Assess tumor regression?
NGS of patients? – at Louvain, Belgium
🆕🗞️Just out
🪺#NEST-1 trial results👇🏾
Are we on the verge of a new drug combo for colon or rectal cancer?
Substantial & brisk responses to just☝🏾dose of BOT🟢➕BAL🔹🔹 immunotherapy.🙌🏾
Pattern & kill is unprecedented🌊.
@ASCO #GI24 @OncoAlert
Abstract 117📍Poster Board H2
Interesting academic session by JM Llovet preceding Dr. Cappuyns her PhD Defence. @UZLeuven @CappuynsSarah @JDekervel @MountSinaiNYC – at Louvain, Belgium
learning about surveillance after curative treatment of colon cancer and the influence of ctDNA in follow-up by @JDekervel #TNS2023 @TNSSymp_2023 – at Bruges, Belgium
Filip Van Herpe retweeted
Exciting news! The CABINET trial has closed early due to promising results! This is very hopeful & meaningful news for the NET community. bit.ly/A021602-Interim
#NCI #LetsTalkAboutNET @ALLIANCE_org @CarcinoidNETs @netcancerday @NANETS1 @CureNETs @HealingNET1
Positive findings from @ALLIANCE_org A021602 (CABINET) trial for patients with advanced neuroendocrine tumors #NETs. To learn more, visit bit.ly/A021602-Interim #NCI #NCTN #CancerResearch @CureNETs @CarcinoidNETs @NETawarenesss
🤔 Especially interesting to see approval without OS benefit AND without seeing the full data first… – at Herent, België
CHMP Supports Approval of Pembro + Trastuzumab/CTy for HER2+, PD-L1+ Gastric/GEJ Cancer
👉Recommendation based on interim data from KEYNOTE-811
🤔Approval despite lack of OS benefit-> interesting...new EMA attitude?
😅I think, the right decision..good for our pts
@myESMO @OncoAlert
1
252
Filip Van Herpe retweeted
CHMP Supports Approval of Pembro + Trastuzumab/CTy for HER2+, PD-L1+ Gastric/GEJ Cancer
👉Recommendation based on interim data from KEYNOTE-811
🤔Approval despite lack of OS benefit-> interesting...new EMA attitude?
😅I think, the right decision..good for our pts
@myESMO @OncoAlert
Filip Van Herpe retweeted
📣Want to know what I've been working on these last 4 years? This is your chance!
A state of the art symposium on Predicting response to Immunotherapy in Liver Cancer
👉Thursday 28th September starting
👉Live in Leuven or online
👉To register : uzleuven.be/nl/kalender/HCC
Together with @CappuynsSarah, no better place than seaside #Barcelona to plan the next event!
𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐧𝐠 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐭𝐨 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐥𝐢𝐯𝐞𝐫 𝐜𝐚𝐧𝐜𝐞𝐫 - Sep 28th, Leuven 🇧🇪 or online💻
🌟speakers: Josep Llovet @DJPinato @siadaniela
Very much looking forward to in depth analysis @myESMO ESMO2023
Positive PDL CPS >1 remains an arguable biomarker… – at Herent, België
Excited to finally share that Keynote 811 survival data in first line HER2+ gastroesophageal cancer will be presented at @myESMO @MSKCancerCenter @MSK_DeptOfMed
businesswire.com/news/home/2…
1
7
574